Given this risk, we thought we'd take a look at whether NGM Biopharmaceuticals ( NASDAQ:NGM ) shareholders should be worried about its cash burn. For the purposes of this article, cash burn is the annual rate at which an unprofitable company spends cash to fund its growth; its negative free cash flow. The first step is to compare its cash burn with its cash reserves, to give us its 'cash runway'.